OncologyTube.com is the first and only free video sharing website dedicated to helping oncology professionals spread knowledge about cancer research through video, audio and other multimedia.
    • OncologyTube

      Site: OncologyTube

    • Products & Pricing
      • Banner Advertising Plans
      • Pre-Roll Advertising
      • Create a Video Release (VR)
      • Boost Earned Media Only $60
      • Create A Deep Dive Conversation
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Buy Advertising Banners
  • Buy Pre-Roll Advertisements
  • Boost Your Earned Media starting at Just $60
  • Create A Deep Dive Conversation
  • Advertising Specifications
  • Our Editorial Process

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5574
  • Acute Myelogenous Leukemia 218
  • Bladder 95
  • Bone Metastases 4
  • Brain 77
  • Breast 433
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 200
  • Chronic Myelogenous Leukemia 49
  • Colorectal 161
  • COVID-19 42
  • Gastrointestinal 175
  • General 334
  • Head and Neck 95
  • Help 3
  • Hematologic Malignancies 185
  • Hodgkin Lymphoma 31
  • Imaging 2
  • Immunotherapy 178
  • Kidney 389
  • Liver 38
  • Lung 72
  • Lymphoma 216
  • Melanoma and Skin 100
  • Multiple Myeloma 507
  • Myeloproliferative Disease 25
  • News 149
  • Non-Hodgkin Lymphoma 78
  • Non-Small Cell Lung Cancer 505
  • Other 512
  • Ovarian 64
  • Pancreatic 100
  • Patient Resources 51
  • Pediatric 6
  • Prostate 285
  • Sickle Cell 22
  • Small Cell Lung Cancer 78
  • Soft Tissue Sarcoma 12
  • Supportive Care 47
  • Testicular 3
  • Urology 16
  • Uterine 9

  • Install
  • Play a Link
  • About
  • Contact
  • Acute Lymphoblastic Leukemia 5574
  • Acute Myelogenous Leukemia 218
  • Bladder 95
  • Bone Metastases 4
  • Brain 77
  • Breast 433
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 200
  • Chronic Myelogenous Leukemia 49
  • Colorectal 161
  • COVID-19 42
  • Gastrointestinal 175
  • General 334
  • Head and Neck 95
  • Help 3
  • Hematologic Malignancies 185
  • Hodgkin Lymphoma 31
  • Imaging 2
  • Immunotherapy 178
  • Kidney 389
  • Liver 38
  • Lung 72
  • Lymphoma 216
  • Melanoma and Skin 100
  • Multiple Myeloma 507
  • Myeloproliferative Disease 25
  • News 149
  • Non-Hodgkin Lymphoma 78
  • Non-Small Cell Lung Cancer 505
  • Other 512
  • Ovarian 64
  • Pancreatic 100
  • Patient Resources 51
  • Pediatric 6
  • Prostate 285
  • Sickle Cell 22
  • Small Cell Lung Cancer 78
  • Soft Tissue Sarcoma 12
  • Supportive Care 47
  • Testicular 3
  • Urology 16
  • Uterine 9
Thomas Hope, MD @thomashopemd @UCSF @SFVAMC #ASCO22 #OncoTwitter  Imaging of solid tumors using 68Ga-FAP-2286
0:05:37

Thomas Hope, MD @thomashopemd @UCSF @SFVAMC #ASCO22 #Onco...

Thomas Hope, MD, Associate Professor in Residence at UC San Francisco. In this video, he speaks about the ASCO 2022 Abstract - Imaging of solid tumors using 68Ga-FAP-2286.

Origins:

Fibroblast Activation Protein (FAP) is a transmembrane protein that is overexpressed on cancer-associated fibroblasts (CAFs) and is prevalent in many epithelial malignancies, implying that FAP is an appealing imaging and therapeutic target. FAP-2286 is a cyclic peptide that binds to FAP and is being tested as a radioligand therapy for patients with FAP-positive solid tumors. It is uncertain what role 68Ga-FAP-2286 plays as a diagnostic agent. We offer an interim investigation of 68Ga-ability FAP-2286's to detect metastatic disease across several cancer types.

Methodology:

This is a first-in-human Phase I/II study using 68Ga-FAP-2286 (NCT04621435), with a total enrollment of 65 patients divided into three cohorts: dosimetry (n = 5), RECIST detectable disease (n = 30), and metastases at risk (n = 30). 27 points had been enrolled by the cutoff date of February 12, 2022. (3 in cohort 1, 15 in cohort 2 and 9 in cohort 3). The five largest lesions from each patient were included in the analysis, and the maximum standardized uptake value (SUVmax) of the 68Ga-FAP-2286 as well as the size (short axis for lymph nodes) were recorded for each lesion. The uptake on the two scans was compared in patients who had an accessible FDG PET performed within 8 weeks after the 68Ga-FAP-2286 PET.

Outcomes:

Nine patients had bladder cancer, five had sarcoma, four had head and neck squamous cell cancer (HNSCCA), three had breast cancer (BC), and three had castration resistant prostate cancer (CRPC) (CRPC). The majority of patients (89 percent, 24/27) had tumors that were positive for uptake on 68Ga-FAP-2286 PET, with 30 lesions measuring 1.5 cm and 17 measuring less than 1.0 cm. A paired FDG PET was performed on 16 subjects. The average SUVmax on 68Ga-FAP-2286 PET was 244 percent higher than on FDG PET in these patients. Only two points demonstrated higher FDG PET uptake than 68Ga-FAP-2286 PET uptake (HNSCCA and DSRCT). The greatest relative uptake was observed in two BC patients (both 3.4 times higher on 68Ga-FAP-2286 PET); the average SUVmax in BC was 16.6. CRPC had the lowest uptake on 68Ga-FAP-2286 PET, with an average SUVmax of 7.0. Sarcoma had uneven uptake, with one point having an SUVmax of 4.5 (Ewing's) and two points having an SUVmax of more than 30. (both undifferentiated pleomorphic). Although sarcoma exhibited a significant 68Ga-FAP-2286 PET uptake, it was comparable to FDG PET uptake across the 5 points (ratio to FDG PET = 1.0).

Observations:

68Ga-FAP-2286 is a potential imaging agent for a variety of malignancies, albeit its benefit is not universal. When compared to FDG PET, BC had the highest absolute and relative uptake, while prostate cancer had the lowest. Further research should be conducted to clarify the scenarios in which 68Ga-FAP-2286 PET may be used to guide therapeutic decision making, as well as which patients may benefit from FAP-targeted radioligand therapy. NCT04621435 is the clinical trial number.

68 Views
2 months ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Imaging Description
Imaging

Podcast Thomas Hope, MD @thomashopemd @UCSF @SFVAMC #ASCO22 #OncoTwitter  Imaging of solid tumors using 68Ga-FAP-2286
0:05:37
Podcast Thomas Hope, MD @thomashopemd @UCSF @SFVAMC #ASCO...
8 Views
2 months ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Thomas Hope, MD @thomashopemd @UCSF @SFVAMC #ASCO22 #OncoTwitter  Imaging of solid tumors using 68Ga-FAP-2286
0:05:37
Thomas Hope, MD @thomashopemd @UCSF @SFVAMC #ASCO22 #Onco...
68 Views
2 months ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Copyright 2022 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592